Skip to main content
. 2021 Dec 6;9(12):e003334. doi: 10.1136/jitc-2021-003334

Figure 1.

Figure 1

Study workflow. BTC, biliary tract cancer; CBR, clinical benefit response; HCC, hepatocellular carcinoma; NCB, non-clinical benefit; OS, overall survival; PD-1, programmed cell death protein 1; PFS, progression-free survival.